In catching up with breast cancer and several hematologic malignancies, non–small cell lung cancer (NSCLC) has made recent advances in targeting genomic mutations that will provide us with the ability to offer more targeted treatment options.
Lung cancer is the leading cause of cancer death in both men and women in the United States.1 It is estimated that in 2009, 219,440 men and women were diagnosed with lung cancer and 159,390 men and women died from the disease.2 From 1975 to 2001, non–small-cell lung cancer (NSCLC) 5-year survival rates have increased from 11.9% to 15.6%. These statistics are independent of sex, race, age, and stage at diagnosis, and make acutely evident that there have been few advances in the treatment of NSCLC.
To sign up for our newsletter or print publications, please enter your contact information below.